Pain Management Nursing
Volume 8, Issue 3, Supplement 1 , Pages S2-S5 , September 2007

Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Opioids

  • Judith A. Paice, PhD, RN, FAAN

      Affiliations

    • Corresponding Author InformationAddress correspondence and reprint requests to Judith A. Paice, PhD, RN, FAAN, Northwestern University; Feinberg School of Medicine, Division of Hematology/Oncology, 676 North St. Clair Street, Suite 850, Chicago, IL 60611.

References 

  1. Andersen G, Christrup L, Sjogren P. Relationships among morphine metabolism, pain and side effects during long-term treatment: an update. Journal of Pain and Symptom Management. 2003;25(1):74–91
  2. Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP. Principles of clinical pharmacology. San Diego, CA: Academic Press; 2001;
  3. Booth M. Opium: A history. New York: St. Martin’s Press; 1996;
  4. de Leon-Casasola OA, Lema MJ. Postoperative epidural opioid analgesia: what are the choices?. Anesthesia and Analgesia. 1996;83(4):867–875
  5. Grudt TJ, Williams JT. Opioid receptors and the regulation of ion conductances. Reviews in the Neurosciences. 1995;6(3):279–286
  6. International Association for the Study of Pain. The paths of pain (1975-2005). Seattle, WA: IASP Press; 2005;
  7. Lauretti GR. Highlights in opioid agonists and antagonists. Expert Review of Neurotherapeutics. 2006;6(4):613–622
  8. Lawrence LL. Legal issues in pain management: striking the balance. Emergency Medicine Clinics of North America. 2005;23(2):573–584
  9. Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. Journal of Pain & Palliative Care Pharmacotherapy. 2005;19(4):13–24
  10. Meldrum ML. Opioids and pain relief: A historical perspective. Seattle, Washington: IASP Press; 2003;
  11. Meuldermans WE, Hurkmans RM, Heykants JJ. Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood. Archives Internationales de Pharmacodynamie et de Thérapie. 1982;257(1):4–19
  12. Olsen GD. Morphine binding to human plasma proteins. Clinical Pharmacology and Therapeutics. 1975;17(1):31–35
  13. Pain and Policies Study Group. Achieving balance in federal and state pain policy: A progress report card. 2nd. Retrieved November 6, 2006, from http://www.painpolicy.wisc.edu/Achieving_Balance/PRC2006.pdf.
  14. Pain and Policies Study Group. Achieving balance in federal and state pain policy: A guide to evaluation. 3rd. Retrieved November 6, 2006, from http://www.painpolicy.wisc.edu/Achieving_Balance/EG2006.pdf.
  15. Pasternak GW. The pharmacology of mu analgesics: from patients to genes. Neuroscientist. 2001;7(3):220–231
  16. Reisine T, Law SF, Blake A, Tallent M. Molecular mechanisms of opiate receptor coupling to G proteins and effector systems. Annals of the New York Academy of Science. 1996;780:168–175
  17. Rogers JF, Nafziger AN, Bertino JS. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. The American Journal of Medicine. 2002;113(9):746–750
  18. Sloan P, Slatkin N, Ahdieh H. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. Support Care Cancer. 2005;13(1):57–65

PII: S1524-9042(07)00046-X

doi: 10.1016/j.pmn.2007.04.001

Pain Management Nursing
Volume 8, Issue 3, Supplement 1 , Pages S2-S5 , September 2007

Article Tools

* Image Usage & Resolution